MHRA’s 2024–25 Annual Report and Accounts and Impact Report show progress on safety, innovation, and regulatory excellence

Marketing authorisations Granted in 2026.

As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.

List of Field Safety Notices: 16-20 February 2026

List of Field Safety Notices from 15 to 19 September 2025.

Amdipharm UK Ltd has informed MHRA that the Patient information leaflet (PIL) in the cartons for the batch listed in this notification includes a superseded PIL.

Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.